INMB INmune Bio Corporation: רווח נקי למניה ב-12 החודשים האחרונים

This price chart for INmune Bio, Inc. (INMB) reflects EPS dynamics currently standing at 71.40. Positive results from Phase 2 trials of the XPro drug for Alzheimer's and potential merger deals are driving the share price growth. The business relies on a universal immune-restoration technology applicable to both oncology and dementia. However, risks remain high due to a lack of sales and the early stages of product development.

The twelve-month trailing earnings per share (EPS TTM) dynamics assess the operational efficiency and the business's ability to generate real income relative to capital. For INmune Bio, Inc. (INMB), whose valuation depends on the success of its Alzheimer's disease therapy, the current state of annual EPS TTM growth reflects the company's financial resilience during a period of costly clinical trials and immune response reprogramming.